Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €4.50 EUR
Change Today +0.11 / 2.51%
Volume 4.8K
ALNOV On Other Exchanges
EN Paris
As of 10:27 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

novacyt (ALNOV) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/15 - €7.64
52 Week Low
08/24/15 - €3.93
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVACYT (ALNOV)

Related News

No related news articles were found.

novacyt (ALNOV) Related Businessweek News

No Related Businessweek News Found

novacyt (ALNOV) Details

Novacyt Société Anonyme develops and sells diagnostic products and services for cancer and infectious diseases. The company offers consumables, which include Gyn vial that holds smear samples and is primarily used for cervical cancer smears; Non-Gyn vial that collects samples and optimizes the quantity of cells collected for use in organ punctures; Novastic, a liquid solution that optimizes the adherence of cells onto the glass slide; and sedimentation systems. It also provides automated analysis instruments, including NovaPrep processor system to perform gynecologic and non-gynecologic preparations from the same fixation medium. The company offers its products through a network of distributors in France and internationally. Novacyt Société Anonyme was founded in 2006 and is based in Vélizy-Villacoublay, France.

61 Employees
Last Reported Date: 05/20/15
Founded in 2006

novacyt (ALNOV) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

novacyt (ALNOV) Key Developments

Novacyt Société Anonyme Reports Sales Results for the First Half of 2015

Novacyt Société Anonyme reported sales results for the first half of 2015. For the period, the company consolidated sales were €4.7 million compared to the €0.5 million for the same period in 2014. Pro forma sales of the Group for first half of 2015 were €4.7 million compared to the €3.8 million in 2014, representing 26% growth which exceeded management’s expectations.

Novacyt Announces Board Changes

Novacyt announced the addition of new members to its Board. Following the Annual General Meeting on June 29, 2015, the company announced the retirement of Fouad Tarabah, a non-executive director and the appointment of two new non-executive directors, Dr. Andrew Heath and Alan Howard. Dr. Andrew Heath joins Novacyt with significant knowledge in capital markets and with international experience in marketing and sales, R & D and business development. Andrew currently serves as Deputy Chairman of Oxford Biomedica plc (since 2010) and as a non-executive director of XL TechGroup Inc., Anew Inc., and IHT Llc. Mr. Alan Howard was most recently Chief Executive of the European Society of Medical Oncology (ESMO), joins the Board having worked extensively in healthcare markets enabling organizations to achieve best standards of governance, corporate compliance and regulatory market compliance. His experience includes Legal and Regulatory Affairs Director of Medtronic Europe based in Paris, CEO of the professional body European Society of Cardiology (ESC), and then more recently CEO of ESMO.

Novacyt Launches New Service to Cervical Cancer Screening Customers

Novacyt has launched a molecular HPV (Human Papillomavirus) service for its customers using the company's NOVAprep liquid-based cytology platform for cervical cancer screening. The new service will use the RealTime High Risk HPV polymerase chain reaction (PCR) assay by Abbott and customers will be provided the possibility to use the same NOVAprep consumable vial and medium for both Novacyt's cytology platform and Abbott's assay. The company has validated the use of Abbott's RealTime High Risk HPV PCR assay with the NOVAprep cytology platform for additional HPV reflex testing when screening for cervical cancer. The testing provides information of whether a patient has HPV infection with any of the 14 high-risk HPV types.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNOV:FP €4.50 EUR +0.11

ALNOV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALNOV.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALNOV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVACYT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at